49 results about "Acute ischemic stroke" patented technology

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

In MRI examinations of patients with acute ischemic stroke, it is often difficult for patients to fix and hold their heads due to impaired consciousness or limb weakness. Therefore, this invention provides a tool that is structurally rational, easy to operate, and effectively enhances the head fixation effect. [Solution] A tool to support MRI examination, comprising a base 1, a head rest member 2 with adjustable anterior-posterior position, a lateral limiting member 3 with an elastic buffer layer, and an adjustment mechanism 4. The head rest member slides relative to the base to adapt to the length of the patient's neck. The lateral limiting member is biased inward by a compression coil spring and flexibly holds both sides of the head with an elastic buffer layer, absorbing and suppressing involuntary movements. The adjustment mechanism uses a single reverse-threaded adjustment rod to synchronously and symmetrically move the left and right limiting plates, enabling precise adjustment according to the head circumference. This effectively limits multi-directional micro-movements of the head during imaging and improves image stability.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The application belongs to the field of Zhuang and Yao medicine treatment of acute ischemic stroke, and discloses a Zhuang and Yao medicine compound medicine, a preparation method and application thereof in treating acute ischemic stroke. The Zhuang and Yao medicine compound medicine comprises the following raw materials in parts by weight: Ficus tikoua 55-62 parts, Camptotheca acuminata 12-17 parts, Ilex hainanensis 26-35 parts and Saposhnikovia divaricata 13-18 parts. The four raw materials are put into clean water, and the raw materials are prepared into a medicinal liquid to obtain the Zhuang and Yao medicine compound medicine. The Zhuang and Yao medicine compound medicine is cheap, convenient to use, has remarkable curative effect, can dredge the dragon road and the toxic evil and toxic side effects of the fire road, and has a simple preparation process.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

This application relates to the field of biomedical engineering, specifically disclosing a stem cell preparation for treating acute ischemic stroke and its preparation method. The preparation comprises a carrier core formed integrally through membrane fusion and an engineered stem cell membrane shell. The carrier core is a homologous stem cell exosome loaded with reactive oxygen species (ROS) scavenging nanoenzymes and can anchor responsive hydrogel microspheres encapsulating neurotrophic factors. The engineered shell covers the core, and its surface is covalently linked to brain-targeting molecules and thermosensitive lipid molecules, the latter of which can expose the target molecules at body temperature for intelligent navigation. The preparation method includes stepwise preparation of the drug-loaded core and functionalized shell, followed by programmed freeze-thaw treatment to induce membrane fusion of the two into a complete preparation. The product of this application can efficiently target ischemic lesions and achieve sequential synergistic treatment by first scavenging ROS and then releasing trophic factors. Its preparation method has advantages such as modularity, mild conditions, and good preservation of bioactivity.

The present application relates to the field of medicine, and discloses an integrated emergency stroke unit having regions. The integrated emergency stroke unit having regions comprises an information interaction area, an imaging examination area, and a thrombolysis treatment area. The information interaction area is provided with a doctor workstation, a comprehensive information monitoring display, and a process-support AI assistant. The imaging examination area is provided with a detection device, a first television display screen, a low-field movable magnetic resonance imager, and an AI-assisted decision-making system. The process-support AI assistant performs automated consultation and assists in nervous system scale scoring by means of voice interaction or touch screen input interaction, and also provides retrieval support for a real-time knowledge base and clinical guidelines. The AI-assisted decision-making system assists in decision-making on the basis of an automated consultation result, a scale scoring result, a detection result, and a head and neck magnetic resonance imaging result, generates a treatment plan, and displays the treatment plan. According to the present application, all diagnosis and treatment activities involved upon the arrival of a patient suffering from acute ischemic stroke at a hospital are integrated into a single space, which can significantly shorten diagnosis and treatment time.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The invention relates to the technical field of deep learning, and discloses an acute ischemic stroke function outcome prediction method and device based on deep learning. The method comprises the following steps: segmenting a preprocessed stroke lesion image sequence and a preprocessed deep marrow vein image sequence by using a deep learning image segmentation model; generating a first image sequence according to the preprocessed stroke lesion image sequence and the lesion segmentation mask sequence; generating a second image sequence according to the preprocessed deep marrow vein image sequence and the deep marrow vein segmentation mask sequence; processing the first image sequence and the second image sequence by using a deep learning classification model to obtain a first functional result prediction result and a second functional result prediction result; and generating a stroke functional result prediction result based on the first functional result prediction result and the second functional result prediction result. According to the invention, the stroke function outcome can be predicted more quickly and accurately.

The invention relates to a polypeptide of SEQ ID NO: 1 for use in the treatment of acute ischaemic stroke (AIS) or in the prevention of the complications of AIS in an adult mammalian subject. The polypeptide can be used in patients in whom AIS is followed by reperfusion of ischemic brain tissue, or in patients in whom AIS is not followed by reperfusion of ischemic brain tissue (patients with permanent cerebral ischemia).

The invention discloses a composition for treating acute ischemic stroke and a preparation method of the composition. The composition is prepared from 80 mg / ml-2. 20 mg / ml of edaravone, 0.48 mg / ml-0. 52 mg / ml of dextroborneol, 0.06 ml / ml-0. 10 ml / ml of propylene glycol, 0.80 mg / ml-1. 20 mg / ml of sodium pyrosulfite and the balance of water for injection, and the pH value of the composition is 3.5-5.5. According to the present invention, the liquid preparation process is optimized and improved, and the step-by-step preparation and mixing process of dissolving edaravone by using 35-45% of the prescription amount of propylene glycol (heating) and dissolving dextroborneol by using the remaining prescription amount of propylene glycol (room temperature) is adopted, such that the drug dissolving effect is ensured, the liquid preparation time can be substantially shortened, the liquid preparation efficiency can be substantially improved, and the industrial production benefit can be well met.

This invention discloses a method for determining collateral circulation indicators based on single-phase CTA, including acquiring single-phase CTA images and DWI images; preprocessing the images to obtain first images at different levels; registering and identifying the blood-supplying brain tissue regions in the first images at different levels to obtain second images at different levels; identifying the ischemic foci area as the vascular aggregation area based on the DWI images, and mapping the vascular aggregation area to the second images at different levels to obtain third images at different levels; calculating the ratio of the area of ​​the vascular aggregation circle to the area of ​​the healthy side vascular circle in the third images at different levels; calculating the mean value based on the ratio and the number of third images, and determining it as the collateral circulation indicator value of the single-phase CTA image to obtain an intuitive and accurate assessment result. This method can be applied to the field of collateral circulation assessment in acute ischemic stroke based on single-phase CTA.

The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acute ischemic stroke.

This invention relates to a method for early identification and screening of acute stroke based on multimodal fusion technology. The method includes step 1: initializing a multimodal inference model, whose output data includes an acute stroke risk assessment, localization analysis of abnormal signs, and targeted early intervention and prognostic recommendations; step 2: collecting and inputting the patient's bio-audio data, bio-video data, and clinical text data into the multimodal inference model; and step 3: based on the acquired multimodal data of the patient, outputting the acute stroke risk assessment result, a localization analysis report based on abnormal signs, and targeted early intervention and prognostic recommendations. This method for early identification and screening of acute stroke enables simple, accurate, and efficient self-examination of acute ischemic stroke in the very early stages, facilitating timely medical attention within the reperfusion therapy window and achieving early detection and treatment.

The invention provides an application of a marker group and / or a reagent for detecting the marker group in preparation of a product for predicting the functional outcome of acute ischemic stroke, the marker group comprises Parabacteroides, Oscillospira, Morganella, Dialister, Acidococcus, Enterobacter, Bifidobacterium, Megasphaera and Enterococcus, and the reagent for detecting the marker group can be used for detecting the functional outcome of acute ischemic stroke, and the marker group can be used for detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke. The invention discloses a marker group for detecting AIS (Automatic Identification System), which comprises any one or more of Pseudomonas, Streptococcus, Butyrimonas, Odobacter, Coprococcus and Roseburia microorganisms, the marker group further comprises a blood coagulation marker, and the marker group or a reagent for detecting the marker group provided by the invention can be used for better predicting the adverse function outcome of AIS patients, and can be used for detecting the adverse function outcome of the AIS patients. The method has good sensitivity and specificity, and a new efficient and accurate prediction means is provided for predicting the functional outcome of AIS patients.

The invention discloses aromatic acid salt of apolipoprotein E mimetic peptide as well as a preparation method and medical application of the aromatic acid salt. The aromatic acid salt, namely the compound ZYH-76, regulates and controls miR-29a-5p, inhibits an iNOS / HMGB1 / TLR4 / MMP-9 signal channel, reduces polarization of A1 type astrocytes, promotes polarization of A2 type astrocytes and protects the integrity of a blood-brain barrier, so that hemorrhagic transformation (HT) after acute ischemic stroke is inhibited. The compound ZYH-76 has a remarkable drug effect in various HT animal models, excellent pharmacokinetic properties and high safety, can be prepared into a freeze-dried preparation for injection, is suitable for HT risk prevention and treatment, and has a good clinical application prospect.

Disclosed is a novel CT denoising method using deep learning to boost the image signal-to-noise ratio for improved disease detection in patients with acute ischemic stroke (AIS). This method reduced the original CT image noise significantly better than BM3D, with SNR improvements in GM, WM, and DG by 2.47×, 2.83×, and 2.64× respectively and CNR improvements in DG / WM and GM / WM by 2.30× and 2.16× respectively. Scans denoised by the proposed model are shown to be visually clearer with preserved anatomy. The disclosed deep learning model significantly reduces image noise and improves signal-to-noise and contrast-to-noise ratios in 380 unseen head NCCT cases.

This invention discloses a biomarker for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke: Syndecan-1 in peripheral blood. This invention provides the application of a substance for detecting Syndecan-1 in peripheral blood in the preparation of products for early diagnosis of prognosis in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing disease progression in patients undergoing intravenous thrombolysis for acute ischemic stroke; or in the preparation of products for assessing the prognosis of patients undergoing intravenous thrombolysis for acute ischemic stroke. Research results indicate that plasma Syndecan-1 levels represent a novel and independent prognostic biomarker that can improve the current risk stratification of patients undergoing intravenous thrombolysis for acute ischemic stroke. Blood tests are easily accepted by patients and can serve as an effective means for early diagnosis, assessment of disease progression, and prognostic evaluation in patients undergoing intravenous thrombolysis for acute ischemic stroke.